News

The molecular target for bone anabolic therapy has been discovered by a research team headed by Hong Kong Baptist University (HKBU), utilising a particular aptamer that acts as an inhibitor of sclerostin, a protein that inhibits bone development. In comparison...

Nykode Therapeutics, a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, has entered into a manufacturing partnership with Richter-Helm BioLogics to supply plasmid DNA for Nykode’s wholly owned and partnered product portfolio. “We are excited about...

The NHS has released encouraging statistics regarding cancer rates in the UK to kick off the new year. Over the past year, more patients than ever before the pandemic received essential NHS cancer treatments. Furthermore, the number of people...

Researchers from Uppsala University in Sweden have released a study on how various antibiotic treatments affect different types of bacteria and how they respond to such treatments. The study's findings highlight the need for rigorously following antibiotic prescription instructions. According...

CardieX Limited, a global health technology company focused on patient-centric healthcare research and improving clinical trial patient outcomes announced a partnership between its ATCOR subsidiary and Invaryant, a data-driven health technology company that empowers individuals with precision AI to...

The Japanese Ministry of Health, Labor, and Welfare (MHLW) has approved AstraZeneca’s immunotherapies Imfinzi (durvalumab) and Imjudo (tremelimumab) to treat advanced liver, biliary tract, and lung cancers. The combination of Imfinzi and Imjudo has been approved to treat unresectable hepatocellular...

Cellectis has entered into a strategic collaboration agreement with Primera Therapeutics to develop a gene editing platform to treat mitochondrial diseases. Primera Therapeutics is launched by Mayflower Bioventures, a cell and gene therapy accelerator stood up from Hibiscus BioVentures and...